MedTrace Logo

Depression and Anxiety in Long Term Coronavirus Disease COVID-19

NCT04893668 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 165

Last updated 2021-06-07

No results posted yet for this study

Summary

Background :

Depression and Anxiety are linked to COVID (Coronavirus Disease)-19 long-term impact through several mechanisms. The possible way is the alteration of neurotransmitter regulation from the interaction of severe acute respiratory syndrome -Coronavirus-2 (SARS-COV2) with Angiotensin-Converting Enzyme 2 (ACE2) receptor, and Dopa Decarboxylase (DDC), an enzyme that associated with the production of dopamine, serotonin, and other neurotransmitters. However, some arguments exist that depression and anxiety occur naturally due to external stressors, as the impact of public health measures, and not associated with physiological changes due to viral infection.

Objective:

1. This study aims to identify whether the patient discharged after COVID 19 treatment has significant changes in serotonin and dopamine level which might induce depression and anxiety internally and,
2. To distinguish external etiologies that might induce depression and anxiety such as social isolation and stress due to public health restriction.

Method:

A prospective longitudinal study of people with the interest exposure is COVID 19 and the primary outcome is Depression, Anxiety, and Neurotransmitter level

Hypothesis:

People with a previous infection of COVID 19 have a significant difference in neurotransmitter level over time and compared to non exposed group and a higher prevalence of anxiety and depression.

Conditions

Interventions

OTHER

Depression

Any participants who develop depression symptoms according to DSM 5 criteria

OTHER

Anxiety

Any participants who develop anxiety symptoms according to DSM 5 criteria

Sponsors & Collaborators

  • Hasanuddin University

    lead OTHER

Principal Investigators

  • Bumi Herman, M.D Ph.D · Chulalongkorn University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-01
Primary Completion
2022-04-01
Completion
2022-06-01

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04893668 on ClinicalTrials.gov